ACC, MedAxiom CEO resigns

Michael Walter | | Cardiovascular Business | Patient Care
Timothy W. Attebery

Attebery

Timothy W. Attebery, DSc, MBA, has resigned as CEO of the American College of Cardiology (ACC) and MedAxiom. The move come as “the result of changing personal and family priorities,” according to an official statement from the ACC.

“We thank Tim for his passion and tireless work for the College's mission and vision over the last year and a half,” said ACC President Athena Poppas, MD. “We wish him well in his future endeavors.”

The ACC Board of Trustees (BOT) has named Cathleen Gates the interim CEO. Cathy has previously served the organization in a number of positions, even working as an interim CEO once before in 2017-2018.

“While Tim will be missed, the BOT has the utmost confidence in Cathy's strong and adept leadership,” Poppas said. “She, along with the talented ACC staff, will continue to ensure that the College's operational effectiveness and strategic direction are aligned to meet the needs of our members around the globe.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Duke specialists to detail the benefits of treating heart failure with Barostim
Family of heart patient who died awarded $45M after suing health system for negligence
Many older heart failure patients are alone and vulnerable—what can be done to help?
Early pregnancy blood pressure patterns tied to hypertension risk years later
Enabling X-ray-free ablation procedures in the EP lab
Detecting coronary inflammation on CT imaging could reshape preventive cardiology

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.